We’re launching Lyria 3.5 in Google Flow Music, with advances across musicality, lyrics, vocals, and creative control
deepmind.google·6d ago
AI Engineering
MIT Technology Review·Jun 9·5 min read
The Download: whole-body rejuvenation drugs and five things to know about AI
TL;DR
A gap exists in effective treatments for aging and rejuvenation. David Sinclair is testing whole-body rejuvenation drugs as part of the XPrize competition.
✦ Why It Matters
Engineers can explore drug development techniques that target aging and healthspan enhancement.
Key Takeaways
- Stay informed about advancements in longevity research.
- Explore opportunities to participate in clinical trials.
- Consider the implications of age-reversing therapies on healthcare.
- Engage with communities focused on healthspan and rejuvenation.
Full Summary
David Sinclair, a prominent longevity researcher at Harvard Medical School, is launching human trials for a drug designed to reverse aging. This initiative is part of the XPrize competition, which offers $101 million to teams that can show significant age restoration in participants.
Sinclair's approach involves administering a mixture of oral drugs to volunteers, aiming for measurable improvements in immune response, cognitive abilities, and muscle function. The competition's grand prize will be awarded to any team that can demonstrate a relative biological age reduction of 10 years or more after one year of treatment.
This research could pave the way for future therapies that significantly extend human healthspan, potentially changing how we approach aging and healthcare.